Incyte (NASDAQ:INCY) Vs. AMGN, GILD, REGN, VRTX, BIIB, SGEN, ALNY, BMRN, RGEN, and EXAS
Should you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry.
Incyte vs.
Gilead Sciences (NASDAQ:GILD) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.
Gilead Sciences has higher revenue and earnings than Incyte. Gilead Sciences is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
Gilead Sciences received 1249 more outperform votes than Incyte when rated by MarketBeat users. Likewise, 79.27% of users gave Gilead Sciences an outperform vote while only 75.46% of users gave Incyte an outperform vote.
Gilead Sciences currently has a consensus target price of $124.58, suggesting a potential upside of 79.10%. Incyte has a consensus target price of $88.30, suggesting a potential upside of 34.24%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gilead Sciences is more favorable than Incyte.
In the previous week, Gilead Sciences had 4 more articles in the media than Incyte. MarketBeat recorded 7 mentions for Gilead Sciences and 3 mentions for Incyte. Gilead Sciences' average media sentiment score of 0.45 beat Incyte's score of 0.26 indicating that Gilead Sciences is being referred to more favorably in the media.
78.1% of Gilead Sciences shares are held by institutional investors. Comparatively, 86.9% of Incyte shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 15.8% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Gilead Sciences has a net margin of 26.91% compared to Incyte's net margin of 18.35%. Gilead Sciences' return on equity of 56.59% beat Incyte's return on equity.
Summary
Gilead Sciences beats Incyte on 12 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Incyte (NASDAQ:INCY) vs. Its Competitors
Incyte Competitors List
